Chartwell Investment Partners LLC Has $686,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Chartwell Investment Partners LLC boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 21.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,410 shares of the company’s stock after buying an additional 14,477 shares during the period. Chartwell Investment Partners LLC’s holdings in Amneal Pharmaceuticals were worth $686,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of AMRX. Rothschild Investment LLC bought a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth about $26,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at $42,000. Atlanta Consulting Group Advisors LLC bought a new position in shares of Amneal Pharmaceuticals in the 1st quarter worth $61,000. nVerses Capital LLC bought a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth $62,000. Finally, Bayesian Capital Management LP bought a new position in Amneal Pharmaceuticals during the first quarter worth about $65,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMRX. StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday. Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Truist Financial lifted their price target on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, October 2nd. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. Finally, Piper Sandler lifted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.00.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $9.25 on Wednesday. The company has a market capitalization of $2.86 billion, a PE ratio of -13.60 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 52-week low of $4.15 and a 52-week high of $9.48. The company has a fifty day moving average of $8.54 and a 200-day moving average of $7.59.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.